Laurus Labs Completes Equity Investment in KRKA Pharma
Filing Summary
Laurus Labs Ltd has finalized an equity investment in KRKA Pharma Private Limited. On December 23, 2025, the company reported acquiring 49,000,000 equity shares of KRKA at a face value of INR 10 each. This transaction, conducted through a rights issue, totals INR 490,000,000. The investment aligns with Regulation 30(7) of SEBI (LODR) Regulations, 2015. This update follows Laurus Labs’ initial intimation on July 25, 2025, regarding the proposed acquisition. KRKA is a joint venture of Laurus Labs, which continues to focus on expanding its pharmaceutical ventures.
Laurus Labs Ltd has completed an equity investment in KRKA Pharma Private Limited. The company announced on December 23, 2025, that it has acquired 49,000,000 equity shares of KRKA. Each share was purchased at a face value of INR 10, resulting in a total investment of INR 490,000,000. This transaction was executed through a rights issue.
This update is in continuation of Laurus Labs’ previous communication dated July 25, 2025, regarding the proposed acquisition of equity shares in KRKA. The investment is in accordance with Regulation 30(7) of SEBI (LODR) Regulations, 2015. KRKA is identified as a joint venture of Laurus Labs.
Laurus Labs is engaged in the pharmaceutical industry, focusing on the development and manufacture of active pharmaceutical ingredients, formulations, and biotechnology. The company is committed to expanding its operations and enhancing its product offerings within the pharmaceutical sector.